The P53/p21Cip1/ Waf1 Pathway Mediates the Effects of SPARC on Melanoma Cell Cycle Progression
Overview
Authors
Affiliations
Secreted protein acidic and rich in cysteine (SPARC), or osteonectin, belongs to the family of matricellular proteins that modulate cell-matrix interactions and cellular functions. SPARC is highly expressed in melanoma, and we reported that SPARC promotes epithelial/mesenchymal-like changes and cell migration. Here, we used siRNA and conditional shRNA to investigate the contribution of tumor-derived SPARC to melanoma cell growth in vitro and in vivo. We found that depletion of SPARC induces G2/M cell cycle arrest and tumor growth inhibition with activation of p53 and induction of p21(Cip1/Waf1) acting as a checkpoint, preventing efficient mitotic progression. In addition, we demonstrate that reduced mesenchymal features and the invasive potential of SPARC-silenced cells are independent of p21(Cip1/Waf1) induction and cell cycle arrest. Importantly, overexpression of SPARC reduces p53 protein levels and leads to an increase in cell number during exponential growth. Our findings indicate that in addition to its well-known function as a mediator of melanoma cell migration and tumor-host interactions, SPARC regulates, in a cell-autonomous manner, cell cycle progression and proliferation through the p53/p21(Cip1/Waf1) pathway.
Ling H, Li Y, Peng C, Yang S, Seto E NAR Cancer. 2024; 6(2):zcae018.
PMID: 38650694 PMC: 11034028. DOI: 10.1093/narcan/zcae018.
Space Flight Enhances Stress Pathways in Human Neural Stem Cells.
Carpo N, Tran V, Biancotti J, Cepeda C, Espinosa-Jeffrey A Biomolecules. 2024; 14(1).
PMID: 38254665 PMC: 10813251. DOI: 10.3390/biom14010065.
Michalakis K, Bakopoulou A, Papachristou E, Vasilaki D, Tsouknidas A, Michailidis N Biomed Res Int. 2021; 2021:5013065.
PMID: 34938808 PMC: 8687839. DOI: 10.1155/2021/5013065.
Epithelial-Mesenchymal Transition in Skin Cancers: A Review.
Hodorogea A, Calinescu A, Antohe M, Balaban M, Nedelcu R, Turcu G Anal Cell Pathol (Amst). 2020; 2019:3851576.
PMID: 31934531 PMC: 6942705. DOI: 10.1155/2019/3851576.
Puglisi R, Bellenghi M, Pontecorvi G, Gulino A, Petrini M, Felicetti F Oncotarget. 2018; 9(7):7567-7581.
PMID: 29484133 PMC: 5800925. DOI: 10.18632/oncotarget.24085.